Ben Creelan

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi et al. · Cancer Cell · 2018 · 1.2K citations · Full text

Immunology, Pathology, Immune Cell Therapy +16

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

Matthew B. Schabath, E A Welsh, William J. Fulp et al. · Oncogene · 2015 · 435 citations

Tumor Biology, Medicine, Lung Adenocarcinoma +11

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Ben Creelan, Chao Wang, Jamie K. Teer et al. · Nature Medicine · 2021 · 400 citations · Full text

Tumor-infiltrating Lymphocyte Treatment, Cancer Immunosurveillance, Medicine +10

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

David Waterhouse, Edward B. Garon, Jason C. Chandler et al. · Journal of Clinical Oncology · 2020 · 223 citations · Full text

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

David R. Spigel, Michael McCleod, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2019 · 184 citations

Checkmate 153, Oncology, Cancer Management +8